PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequestration
- PMID: 12902986
- DOI: 10.1038/sj.onc.1206643
PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequestration
Abstract
Papillary renal cell carcinomas are associated with chromosomal translocations involving the helix-loop-helix leucine-zipper region of the TFE3 gene on the X chromosome. These translocations lead to the expression of TFE3 chimeras of PRCC, RCC17, NonO and PSF (PTB-associated splicing factor). In this study, we explored the role of PSF-TFE3 fusion protein in mediating cell transformation. Unlike wild-type TFE3 or PSF, which are nuclear proteins, PSF-TFE3 is not a nuclear protein and is targeted to the endosomal compartment. Although PSF-TFE3 has no effect on the nuclear localization of wild-type PSF, it sequesters wild-type TFE3 as well as p53 in the extranuclear compartment leading to functionally null p53 and TFE3 cells. In UOK-145 papillary renal carcinoma cells, which endogenously express PSF-TFE3, siRNA complementary to the PSF-TFE3 fusion junction leads to a reduction in PSF-TFE3 and redistribution of endogenous TFE3 and p53 from the cytoplasmic compartment to the nucleus. Our results indicate that PSF-TFE3 acts through a novel mechanism, and exports TFE3, p53 and possibly other factors from the nucleus to the cytoplasm for degradation leading to the transformed phenotype. Thus, PSF-TFE3 is a promising target for the treatment for a subset of renal cell carcinomas.
Similar articles
-
Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas.Oncogene. 2007 Jan 11;26(2):277-83. doi: 10.1038/sj.onc.1209783. Epub 2006 Jul 10. Oncogene. 2007. PMID: 16832349
-
Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins.Oncogene. 2000 Jan 6;19(1):69-74. doi: 10.1038/sj.onc.1203255. Oncogene. 2000. PMID: 10644981
-
A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23).Oncogene. 2003 Aug 14;22(34):5374-8. doi: 10.1038/sj.onc.1206686. Oncogene. 2003. PMID: 12917640
-
Translocation carcinomas of the kidney.Clin Lab Med. 2005 Jun;25(2):363-78. doi: 10.1016/j.cll.2005.01.008. Clin Lab Med. 2005. PMID: 15848741 Review.
-
Molecular mechanisms underlying the MiT translocation subgroup of renal cell carcinomas.Cytogenet Genome Res. 2007;118(2-4):157-65. doi: 10.1159/000108296. Cytogenet Genome Res. 2007. PMID: 18000366 Review.
Cited by
-
Xp11.2 translocation renal cell carcinoma with PSF-TFE3 rearrangement.Diagn Mol Pathol. 2013 Jun;22(2):107-11. doi: 10.1097/PDM.0b013e318278962e. Diagn Mol Pathol. 2013. PMID: 23628822 Free PMC article.
-
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.Blood. 2007 Oct 1;110(7):2600-9. doi: 10.1182/blood-2006-01-028647. Epub 2007 May 30. Blood. 2007. PMID: 17537995 Free PMC article.
-
The transcription factors TFE3 and TFEB amplify p53 dependent transcriptional programs in response to DNA damage.Elife. 2018 Dec 6;7:e40856. doi: 10.7554/eLife.40856. Elife. 2018. PMID: 30520728 Free PMC article.
-
Hacking RNA: Hakai promotes tumorigenesis by enhancing the RNA-binding function of PSF.Cell Cycle. 2009 Nov 15;8(22):3648-51. doi: 10.4161/cc.8.22.9909. Epub 2009 Nov 24. Cell Cycle. 2009. PMID: 19855157 Free PMC article. Review.
-
Xp11 translocation renal cell carcinoma in adults: a clinicopathological and comparative genomic hybridization study.Int J Clin Exp Pathol. 2013 Dec 15;7(1):236-45. eCollection 2014. Int J Clin Exp Pathol. 2013. PMID: 24427344 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous